Robert C. Olney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert C. Olney has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Eric A. Espiner
University of Otago, Christchurch, New Zealand
5 shared publications- Timothy C. R. Prickett
Department of Medicine, University of Otago, Christchurch, New Zealand
5 shared publications Edward B Mougey
2 shared publicationsJianwei Wang
2 shared publicationsJoan C. Han
Unit on Metabolism and Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development Bethesda MD USA
2 shared publications- Michael B. Bober
Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA
2 shared publications
Latest Publications
- 16 June 2016
- Published by Wiley in Clinical Endocrinology
- Vol. 85 (4) , 561-568
Dynamic response of C‐type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature
Summary: Objective: C‐type natriuretic peptide (CNP) and its aminoterminal propeptide (NTproCNP) are potential biomarkers of recombinant human growth hormone (rhGH) efficacy. The objective of this study was to describe the pharmacodynamics of plasma CNP and NTproCNP levels in response to rhGH treatment and to identify the optimal time of sampling after starting rhGH.Design: This was a prospective, observational study. Subjects were treated with rhGH for 1 year, with blood sampled at regular intervals.Patients: Eighteen prepubertal children, eight with low levels of GH on biochemical testing and ten with idiopathic short stature, completed the study.Measurements: Blood levels of CNP, NTproCNP, GH, insulin‐like growth factor‐I, leptin and bone‐specific alkaline phosphatase were measured. Anthropometrics were obtained.Results: Plasma levels of both CNP and NTproCNP reached peak levels 7–28 days after starting rhGH treatment and then declined to intermediate levels through the first year. Plasma NTproCNP levels after 14 days trended towards a correlation with height velocity after 6 and 12 months of treatment. Unexpectedly, serum GH levels measured 2 and 28 days after starting rhGH correlated strongly with height velocity after 6 and 12 months of treatment.Conclusions: This study identified 14 days after starting rhGH treatment as the optimal time for assessing CNP and NTproCNP levels as biomarkers of rhGH efficacy. Additionally, we identified GH levels as a potential biomarker. Larger, prospective studies are now needed to test the clinical utility of these biomarkers.
- 16 June 2016
- Published by Wiley in Clinical Endocrinology
- Vol. 85 (4) , 561-568
Dynamic response of C‐type natriuretic peptide and its aminoterminal propeptide (NTproCNP) to growth hormone treatment in children with short stature
Summary: Objective: C‐type natriuretic peptide (CNP) and its aminoterminal propeptide (NTproCNP) are potential biomarkers of recombinant human growth hormone (rhGH) efficacy. The objective of this study was to describe the pharmacodynamics of plasma CNP and NTproCNP levels in response to rhGH treatment and to identify the optimal time of sampling after starting rhGH.Design: This was a prospective, observational study. Subjects were treated with rhGH for 1 year, with blood sampled at regular intervals.Patients: Eighteen prepubertal children, eight with low levels of GH on biochemical testing and ten with idiopathic short stature, completed the study.Measurements: Blood levels of CNP, NTproCNP, GH, insulin‐like growth factor‐I, leptin and bone‐specific alkaline phosphatase were measured. Anthropometrics were obtained.Results: Plasma levels of both CNP and NTproCNP reached peak levels 7–28 days after starting rhGH treatment and then declined to intermediate levels through the first year. Plasma NTproCNP levels after 14 days trended towards a correlation with height velocity after 6 and 12 months of treatment. Unexpectedly, serum GH levels measured 2 and 28 days after starting rhGH correlated strongly with height velocity after 6 and 12 months of treatment.Conclusions: This study identified 14 days after starting rhGH treatment as the optimal time for assessing CNP and NTproCNP levels as biomarkers of rhGH efficacy. Additionally, we identified GH levels as a potential biomarker. Larger, prospective studies are now needed to test the clinical utility of these biomarkers.
- 1 November 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (11) , 4206-4211
C-Type Natriuretic Peptide (CNP) Levels Are Altered in Boys with Klinefelter Syndrome
B-type natriuretic peptide (BNP) expression in vitro is up-regulated by the protein coded by the short stature homeobox gene (SHOX). C-type natriuretic peptide (CNP) is a paracrine regulatory factor of the growth plate that plays a key role in endochondral growth and shares clearance pathways with BNP. We explored the possibility that alterations in natriuretic peptide regulation may play a role in the overgrowth of boys with Klinefelter syndrome. The objectives of the study were to document the blood levels of amino-terminal propeptide of B-type natriuretic peptide (NTproBNP), CNP, and its amino-terminal propeptide (NTproCNP) in boys with Klinefelter syndrome and compare values with age- and height-matched control subjects. This was a prospective, case-controlled, observational study. Participants were 24 healthy boys with Klinefelter syndrome between 4 and 14 yr of age. Data from sex-, age-, and height-matched healthy controls were obtained from subjects participating in a previously described study. Plasma levels of NTproBNP and CNP were lower, whereas levels of NTproCNP were higher in boys with Klinefelter syndrome compared with published reference ranges. In addition, CNP levels were lower and NTproCNP levels higher than in sex-, age-, and height-matched controls. In contrast to plasma NTproBNP, CNP production and clearance are increased in boys with Klinefelter syndrome. Together these findings argue against an interaction between BNP with CNP in the growth plate. Why CNP peptide levels are altered in Klinefelter syndrome remains to be explored.
- 1 November 2012
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (11) , 4206-4211
C-Type Natriuretic Peptide (CNP) Levels Are Altered in Boys with Klinefelter Syndrome
B-type natriuretic peptide (BNP) expression in vitro is up-regulated by the protein coded by the short stature homeobox gene (SHOX). C-type natriuretic peptide (CNP) is a paracrine regulatory factor of the growth plate that plays a key role in endochondral growth and shares clearance pathways with BNP. We explored the possibility that alterations in natriuretic peptide regulation may play a role in the overgrowth of boys with Klinefelter syndrome. The objectives of the study were to document the blood levels of amino-terminal propeptide of B-type natriuretic peptide (NTproBNP), CNP, and its amino-terminal propeptide (NTproCNP) in boys with Klinefelter syndrome and compare values with age- and height-matched control subjects. This was a prospective, case-controlled, observational study. Participants were 24 healthy boys with Klinefelter syndrome between 4 and 14 yr of age. Data from sex-, age-, and height-matched healthy controls were obtained from subjects participating in a previously described study. Plasma levels of NTproBNP and CNP were lower, whereas levels of NTproCNP were higher in boys with Klinefelter syndrome compared with published reference ranges. In addition, CNP levels were lower and NTproCNP levels higher than in sex-, age-, and height-matched controls. In contrast to plasma NTproBNP, CNP production and clearance are increased in boys with Klinefelter syndrome. Together these findings argue against an interaction between BNP with CNP in the growth plate. Why CNP peptide levels are altered in Klinefelter syndrome remains to be explored.
- 21 March 2012
- Published by Wiley in Clinical Endocrinology
- Vol. 77 (3) , 416-422
Amino‐terminal propeptide of C‐type natriuretic peptide (NTproCNP) predicts height velocity in healthy children
Summary: Objective: C‐type natriuretic peptide (CNP) is a paracrine regulatory factor of the growth plate and plays a key role in endochondral growth. Its amino‐terminal propeptide (NTproCNP) is an equimolar product of CNP biosynthesis and is easily measured in plasma. Preliminary studies suggest that NTproCNP levels correlate with height velocity in sheep and children. The objectives of the study were to correlate NTproCNP levels with height velocity and to define the reference range for plasma CNP and NTproCNP across childhood.Design: This was a prospective, cross‐sectional, observational study of healthy children.Patients: Participants were 258 healthy children between 2 months and 20 years of age.Measurements: Anthropometrics were obtained and CNP and NTproCNP levels were determined by radioimmunoassay.Results: For both sexes, CNP and NTproCNP levels were high in infancy, lower in early childhood, rising during puberty, then falling to low adult levels. Levels of NTproCNP peaked at 14·1 years in boys and 11·9 years in girls, coincident with the age of peak height velocity. Levels of NTproCNP varied with pubertal status, peaking at genital Tanner stage IV in boys and III in girls. There was a highly significant correlation between NTproCNP and height velocity.Conclusions: C‐type natriuretic peptide plays an integral role in endochondral growth. We show here that CNP synthesis (as measured by NTproCNP levels in plasma) is closely related to linear growth in healthy children at all ages. We propose NTproCNP as a biomarker of linear growth.
- 21 March 2012
- Published by Wiley in Clinical Endocrinology
- Vol. 77 (3) , 416-422
Amino‐terminal propeptide of C‐type natriuretic peptide (NTproCNP) predicts height velocity in healthy children
Summary: Objective: C‐type natriuretic peptide (CNP) is a paracrine regulatory factor of the growth plate and plays a key role in endochondral growth. Its amino‐terminal propeptide (NTproCNP) is an equimolar product of CNP biosynthesis and is easily measured in plasma. Preliminary studies suggest that NTproCNP levels correlate with height velocity in sheep and children. The objectives of the study were to correlate NTproCNP levels with height velocity and to define the reference range for plasma CNP and NTproCNP across childhood.Design: This was a prospective, cross‐sectional, observational study of healthy children.Patients: Participants were 258 healthy children between 2 months and 20 years of age.Measurements: Anthropometrics were obtained and CNP and NTproCNP levels were determined by radioimmunoassay.Results: For both sexes, CNP and NTproCNP levels were high in infancy, lower in early childhood, rising during puberty, then falling to low adult levels. Levels of NTproCNP peaked at 14·1 years in boys and 11·9 years in girls, coincident with the age of peak height velocity. Levels of NTproCNP varied with pubertal status, peaking at genital Tanner stage IV in boys and III in girls. There was a highly significant correlation between NTproCNP and height velocity.Conclusions: C‐type natriuretic peptide plays an integral role in endochondral growth. We show here that CNP synthesis (as measured by NTproCNP levels in plasma) is closely related to linear growth in healthy children at all ages. We propose NTproCNP as a biomarker of linear growth.
- 1 November 2009
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 72 (Suppl. 1) , 30-35
Mechanisms of Impaired Growth: Effect of Steroids on Bone and Cartilage
Background: Long-term treatment with high-dose glucocorticoids (GCs) has profound effects on bone metabolism and linear growth. Bone metabolism is a balance between bone resorption by osteoclasts and new bone formation by osteoblasts. Systemically, GC treatment reduces circulating levels of estrogen and modestly increases parathyroid hormone levels. At the local level, GCs decrease insulin-like growth factor I (IGF-I) production, induce IGF-I resistance and increase nuclear factor κB ligand production by osteoblasts. These alterations inhibit new bone formation and stimulate bone resorption, with a net loss of bone over time. Clinically, this results in decreased bone mineral density, osteoporosis and increased risk for fracture. Local effects of GCs at the growth plate include reduction of IGF-I production, inducing IGF-I resistance and reducing production of C-type natriuretic peptide, which results in a reduction of chondrocyte proliferation, matrix synthesis and hypertrophy. These reductions in chondrocyte function result in decreased linear growth. Conclusions: The effects of GCs on bone metabolism and linear growth are sensitive and specific and represent an evolutionary adaptation to redirect resources during times of physiologic stress. Since many of these effects result from alterations in IGF-I production, growth hormone therapy is a potential approach to ameliorate these problems.
- 1 November 2009
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 72 (Suppl. 1) , 30-35
Mechanisms of Impaired Growth: Effect of Steroids on Bone and Cartilage
Background: Long-term treatment with high-dose glucocorticoids (GCs) has profound effects on bone metabolism and linear growth. Bone metabolism is a balance between bone resorption by osteoclasts and new bone formation by osteoblasts. Systemically, GC treatment reduces circulating levels of estrogen and modestly increases parathyroid hormone levels. At the local level, GCs decrease insulin-like growth factor I (IGF-I) production, induce IGF-I resistance and increase nuclear factor κB ligand production by osteoblasts. These alterations inhibit new bone formation and stimulate bone resorption, with a net loss of bone over time. Clinically, this results in decreased bone mineral density, osteoporosis and increased risk for fracture. Local effects of GCs at the growth plate include reduction of IGF-I production, inducing IGF-I resistance and reducing production of C-type natriuretic peptide, which results in a reduction of chondrocyte proliferation, matrix synthesis and hypertrophy. These reductions in chondrocyte function result in decreased linear growth. Conclusions: The effects of GCs on bone metabolism and linear growth are sensitive and specific and represent an evolutionary adaptation to redirect resources during times of physiologic stress. Since many of these effects result from alterations in IGF-I production, growth hormone therapy is a potential approach to ameliorate these problems.
- 1 May 2008
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 121 (5) , 890-897
Healthy Children With Frequent Fractures: How Much Evaluation Is Needed?
OBJECTIVE. We performed a case-control study to determine whether occult bone disease is associated with a history of frequent fractures in children. METHODS. Healthy children with ≥2 incidences of low-energy fractures were recruited (n = 68). Children with no history of fractures served as control subjects (n = 57). Food logs, activity surveys, physical examinations, laboratory tests, and dual-energy radiographic absorptiometry were used. RESULTS. Bone mineral density z scores were significantly reduced in case subjects, compared with control subjects. Three case subjects (4.3%) and 1 control subject (1.8%) had bone mineral density z scores below the expected range. Of those 4 subjects, 2 had dairy avoidance and 2 had delayed puberty. An additional case subject had evidence of vitamin D deficiency. A significant number of subjects (20% of case subjects and 23% of control subjects) had idiopathic hypercalcuria, based on 24-hour urine collections. Among the case subjects, bone mineral density z scores were significantly lower for those with idiopathic hypercalcuria. Among the control subjects, the presence of idiopathic hypercalcuria did not affect bone mineral density. The case subjects with idiopathic hypercalcuria accounted for virtually all of the differences in bone mineral density between the case and control groups. Analysis of parathyroid hormone and 1,25-dihydroxy-vitamin D levels showed that children with frequent fractures and hypercalcuria had renal hypercalcuria, whereas children with no fractures and hypercalcuria had absorptive hypercalcuria. CONCLUSIONS. We identified a significant association between a history of frequent fractures and hypercalcuria in children. We propose that the appropriate screening evaluation for children who present with a history of frequent fractures consists of a dietary history targeted at calcium and vitamin D intakes, a physical examination to assess for pubertal delay, and urinary calcium concentration/creatinine ratio determination to assess for hypercalcuria. Children with abnormalities in this screening should undergo dual-energy radiographic absorptiometry and appropriate evaluation.
- 1 May 2008
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 121 (5) , 890-897
Healthy Children With Frequent Fractures: How Much Evaluation Is Needed?
OBJECTIVE. We performed a case-control study to determine whether occult bone disease is associated with a history of frequent fractures in children. METHODS. Healthy children with ≥2 incidences of low-energy fractures were recruited (n = 68). Children with no history of fractures served as control subjects (n = 57). Food logs, activity surveys, physical examinations, laboratory tests, and dual-energy radiographic absorptiometry were used. RESULTS. Bone mineral density z scores were significantly reduced in case subjects, compared with control subjects. Three case subjects (4.3%) and 1 control subject (1.8%) had bone mineral density z scores below the expected range. Of those 4 subjects, 2 had dairy avoidance and 2 had delayed puberty. An additional case subject had evidence of vitamin D deficiency. A significant number of subjects (20% of case subjects and 23% of control subjects) had idiopathic hypercalcuria, based on 24-hour urine collections. Among the case subjects, bone mineral density z scores were significantly lower for those with idiopathic hypercalcuria. Among the control subjects, the presence of idiopathic hypercalcuria did not affect bone mineral density. The case subjects with idiopathic hypercalcuria accounted for virtually all of the differences in bone mineral density between the case and control groups. Analysis of parathyroid hormone and 1,25-dihydroxy-vitamin D levels showed that children with frequent fractures and hypercalcuria had renal hypercalcuria, whereas children with no fractures and hypercalcuria had absorptive hypercalcuria. CONCLUSIONS. We identified a significant association between a history of frequent fractures and hypercalcuria in children. We propose that the appropriate screening evaluation for children who present with a history of frequent fractures consists of a dietary history targeted at calcium and vitamin D intakes, a physical examination to assess for pubertal delay, and urinary calcium concentration/creatinine ratio determination to assess for hypercalcuria. Children with abnormalities in this screening should undergo dual-energy radiographic absorptiometry and appropriate evaluation.
- Open Access
- 1 November 2007
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (11) , 4294-4298
Amino-Terminal Propeptide of C-Type Natriuretic Peptide and Linear Growth in Children: Effects of Puberty, Testosterone, and Growth Hormone
Context: C-type natriuretic peptide (CNP), a paracrine factor of the growth plate, plays a key role in stimulating bone growth. The amino-terminal propeptide of CNP (NTproCNP) is produced in equimolar amounts with CNP and is measurable in plasma, providing a potential biomarker for growth plate activity and, hence, linear growth. Objective: We explored the effects of puberty, testosterone, and GH treatment on NTproCNP levels in normal and short-statured children. Design: This was a retrospective analysis of samples obtained during previous studies. Setting: The study was conducted at a pediatric clinical research center. Subjects: Children with short stature due to GH deficiency, idiopathic short stature (ISS), or constitutional delay of growth and maturation (CDGM) were studied (n = 37). A cohort of normal-statured adolescent boys was also studied (n = 23). Interventions: Children with GH deficiency and ISS were studied before and during testosterone and/or GH treatment. Boys with CDGM and healthy controls were studied once. Main Outcome Measures: The main outcomes were NTproCNP levels before and during growth-promoting therapy and during pubertal growth. Results: Children with short stature due to GH deficiency, ISS, or CDGM had comparable baseline levels of NTproCNP, and levels increased markedly in response to GH or testosterone treatment. In boys with CDGM, levels were comparable with height-matched controls but were less than those from age-matched controls. In healthy boys, NTproCNP appears to peak with the pubertal growth spurt. Conclusions: NTproCNP levels increase during growth-promoting therapy and are increased during puberty in boys. This novel biomarker of growth may have clinical utility in the evaluation of children with short stature and for monitoring growth-promoting therapy.
- 1 November 2007
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (11) , 4294-4298
Open AccessAmino-Terminal Propeptide of C-Type Natriuretic Peptide and Linear Growth in Children: Effects of Puberty, Testosterone, and Growth Hormone
Context: C-type natriuretic peptide (CNP), a paracrine factor of the growth plate, plays a key role in stimulating bone growth. The amino-terminal propeptide of CNP (NTproCNP) is produced in equimolar amounts with CNP and is measurable in plasma, providing a potential biomarker for growth plate activity and, hence, linear growth. Objective: We explored the effects of puberty, testosterone, and GH treatment on NTproCNP levels in normal and short-statured children. Design: This was a retrospective analysis of samples obtained during previous studies. Setting: The study was conducted at a pediatric clinical research center. Subjects: Children with short stature due to GH deficiency, idiopathic short stature (ISS), or constitutional delay of growth and maturation (CDGM) were studied (n = 37). A cohort of normal-statured adolescent boys was also studied (n = 23). Interventions: Children with GH deficiency and ISS were studied before and during testosterone and/or GH treatment. Boys with CDGM and healthy controls were studied once. Main Outcome Measures: The main outcomes were NTproCNP levels before and during growth-promoting therapy and during pubertal growth. Results: Children with short stature due to GH deficiency, ISS, or CDGM had comparable baseline levels of NTproCNP, and levels increased markedly in response to GH or testosterone treatment. In boys with CDGM, levels were comparable with height-matched controls but were less than those from age-matched controls. In healthy boys, NTproCNP appears to peak with the pubertal growth spurt. Conclusions: NTproCNP levels increase during growth-promoting therapy and are increased during puberty in boys. This novel biomarker of growth may have clinical utility in the evaluation of children with short stature and for monitoring growth-promoting therapy.
- 1 July 2006
- Published by Elsevier in Growth Hormone & IGF Research
- Vol. 16, 6-14
C-type natriuretic peptide in growth: A new paradigm
- 1 July 2006
- Published by Elsevier in Growth Hormone & IGF Research
- Vol. 16, 6-14
C-type natriuretic peptide in growth: A new paradigm
- 1 April 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (4) , 1229-1232
Heterozygous Mutations in Natriuretic Peptide Receptor-B (NPR2) Are Associated with Short Stature
C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear. The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations. This was a case-control study from the general community. Thirty-nine members of a family in which one member has AMDM were studied. This was an observational study. The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers. Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were -1.8 +/- 1.1 (mean +/- sd), which was significantly less than the 23 noncarrier family members (-0.4 +/- 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers. We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.
- 1 April 2006
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 91 (4) , 1229-1232
Heterozygous Mutations in Natriuretic Peptide Receptor-B (NPR2) Are Associated with Short Stature
C-type natriuretic peptide (CNP) is an important regulator of skeletal growth. Loss-of-function mutations affecting the CNP receptor natriuretic peptide receptor-B (gene NPR2) cause the autosomal recessive skeletal dysplasia, acromesomelic dysplasia, Maroteaux type (AMDM). The phenotype of heterozygous carriers of NPR2 mutations is less clear. The objective of the study was to determine the phenotypic features of heterozygous carriers of NPR2 mutations. This was a case-control study from the general community. Thirty-nine members of a family in which one member has AMDM were studied. This was an observational study. The primary measure was stature, with the hypothesis that carriers have reduced stature compared with noncarriers. Sixteen family members were NPR2 mutation carriers. Height z-scores of these carriers were -1.8 +/- 1.1 (mean +/- sd), which was significantly less than the 23 noncarrier family members (-0.4 +/- 0.8, P < 0.0005) and the general population (P < 0.0005). However, there was no difference in body proportion between carriers and noncarriers. The proband with AMDM had low IGF-I levels and evidence of GH resistance, as well as very high plasma levels of CNP and its amino-terminal propeptide. Levels of these peptides were normal in the heterozygous carriers. We have shown that heterozygous mutations in NPR2 are associated with short stature. Assuming one in 700 people unknowingly carry an NPR2 mutation, our data suggest that approximately one in 30 individuals with idiopathic short stature are carriers of NPR2 mutations.